Gossamer Bio Downgraded with $1 Target After Phase 3 PROSERA Shortfall
Leerink Partners set a $1 price target for Gossamer Bio, implying roughly 64% upside, but downgraded the stock to Market Perform after mixed Phase 3 PROSERA results. The trial showed a 28.2m vs. 13.5m Six-Minute Walk Distance improvement (p=0.032) yet missed its key statistical threshold, sending shares down over 80% and trimming market cap to about $98 million.
1. Price Target and Downgrade
Leerink Partners assigned a $1 price target for Gossamer Bio, reflecting potential upside of approximately 63.8%, but this came with a downgrade from Outperform to Market Perform based on the company’s recent clinical data. The revised outlook underscores caution around seralutinib’s ability to meet primary endpoints.
2. PROSERA Trial Outcomes
In the Phase 3 PROSERA study, seralutinib-treated patients showed a median Six-Minute Walk Distance gain of 28.2 meters versus 13.5 meters for placebo. Despite a p-value of 0.032 suggesting potential efficacy, the trial narrowly missed its prespecified statistical threshold, raising questions about definitive clinical benefit.
3. Market Reaction and Financial Impact
Following the topline readout, shares plunged over 80% this year, driving the company’s market capitalization down to around $98 million. Trading volume surged as investors weighed the impact of the mixed results on future regulatory engagement and partnership prospects.